

Accepted Manuscript

Title: Fludarabine and Busulfan Versus Fludarabine, Cyclophosphamide and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma

Author: Narendranath Epperla, Kwang Woo Ahn, Philippe Armand, Samantha Jaglowski, Sairah Ahmed, Vaishalee P. Kenkre, Bipin Savani, Madan Jagasia, Nirav N. Shah, Timothy S. Fenske, Ana Sureda, Sonali M. Smith, Mehdi Hamadani

PII: S1083-8791(17)30770-X
DOI: <https://doi.org/doi:10.1016/j.bbmt.2017.10.011>
Reference: YBBMT 54825


To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 23-8-2017

Accepted date: 5-10-2017

Please cite this article as: Narendranath Epperla, Kwang Woo Ahn, Philippe Armand, Samantha Jaglowski, Sairah Ahmed, Vaishalee P. Kenkre, Bipin Savani, Madan Jagasia, Nirav N. Shah, Timothy S. Fenske, Ana Sureda, Sonali M. Smith, Mehdi Hamadani, Fludarabine and Busulfan Versus Fludarabine, Cyclophosphamide and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma, *Biology of Blood and Marrow Transplantation* (2017), <https://doi.org/doi:10.1016/j.bbmt.2017.10.011>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.

Narendranath Epperla^{1,2}, Kwang Woo Ahn³, Philippe Armand⁴ Samantha Jaglowski², Sairah Ahmed⁵, Vaishalee P. Kenkre⁶, Bipin Savani⁷, Madan Jagasia⁷, Nirav N. Shah¹, Timothy S. Fenske¹, Ana Sureda⁸, Sonali M. Smith⁹, Mehdi Hamadani^{1,10}

¹Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

²Division of Hematology, The Ohio State University Medical Center, Columbus, OH

³Center for International Blood and Marrow Transplant Research, Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI

⁴Department of Medical Oncology/Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA

⁵Department of Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX

⁶Division of Hematology and Oncology, University of Wisconsin, Madison, WI, USA.

⁷Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN

⁸Servei d'Hematologica, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain,

⁹Section of Hematology/Oncology, The University of Chicago, Chicago, IL

¹⁰Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

Corresponding author: Mehdi Hamadani, MD, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Suite C5500, Milwaukee, WI 53226, USA; Phone: 414-805-0643; Fax: 414-805-0714; E-mail: mhamadani@mcw.edu

Short title: Flu/Bu vs FCR RIC HCT in FL

Text pages = 18, Number of figures = 2, Number of tables = 5, Number of references = 30

Keywords: FCR; Flu/Bu; follicular lymphoma; reduced-intensity conditioning; allogeneic HCT

Download English Version:

<https://daneshyari.com/en/article/8430531>

Download Persian Version:

<https://daneshyari.com/article/8430531>

[Daneshyari.com](https://daneshyari.com)